Continuing Education

January 19, 2024

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Endocrine Society.  

AMA PRA Category 1™ Credits 

The Endocrine Society designates this activity for a maximum of 26 AMA PRA Category 1 Credits* for both premium and standard registrants. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. Following confirmation with groups such as AAPA and AANP, participation credit awarded for an activity that is eligible for AMA PRA Category 1 qualifies as CME and that should be claimed by individuals who do not hold an MD or DO designation. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

*Premium registrants will be able to earn additional AMA PRA Category 1 credits via premium access to the ENDO 2024 recording library, available in late summer 2024.

American Board of Internal Medicine Maintenance of Certification (MOC) Points

Successful completion of this CME activity, which includes participation in the overall conference evaluation in the Center for Learning, enables the participant to earn up to 26 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. At the time of submission, please ensure your full name, Diplomate ID and birthdate match ABIM’s records or MOC points may be rejected by ABIM.

Note: All attendees interested in obtaining CME and/or MOC for their participation in ENDO 2024 must visit the Center for Learning to complete the evaluation by August 7, 2024. Completion of session evaluations in the mobile app does not count towards credit claiming.

American Board of Pediatrics Maintenance of Certification (MOC) Points

Successful completion of this CME activity, which includes participation in the overall conference evaluation in the Center for Learning, enables the learner to earn up to 16.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

European Accreditation Council for Continuing Medical Education

The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: European physicians attending an event in the USA had their credits recognized in Europe and American physicians attending an event in Europe had their credits recognized in the USA.

The Endocrine Society designates this educational activity for a maximum of 26 AMA PRA Category 1 Credit(s)™ for standard and premium registrants. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Royal College of Physicians and Surgeons of Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. Instructions regarding this conversion can be found here.

CREDIT CLAIM DEADLINE IS AUGUST 7, 2024 FOR ALL REGISTRANT TYPES.

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following AMSC members reported relevant financial relationships:

Irina Bancos, MD, Elsevier, writer, Dynamed, reviewer, Endocrine Society Educational initiatives

Stephanie Anne Fish, PhD, American Board of Internal Medicine, write questions for endocrine maintenance of certification

Lauren Michelle Fishbein, MD, PhD, Lantheus/Azedra, Consultant, Endocrine Society, Associate Editor Endocrine Review

Christa E. Flueck, MD, Novo Nordisk, advisor, grantee, Merck, grantee, Pfizer, advisor, grantee, Sandoz, grantee, speaker, EffRx, advisor, Swiss National Science Foundation, grantee, European Society Paediatric Endocrinology, grantee, committee member

Daniel E. Frigo, PhD, -GTx, Inc, paid consultant and laboratory funding, Hummingbird Bioscience, Maia Biotechnology,-Alms Therapeutics,-Barricade Therapeutic, -Hinova Pharmaceuticals, Inc.

Ole-Petter Hamnvik, MBBChBAO, MMSc, MRCPI, Education Editor: New England Journal of Medicine

Edward Chiaming Hsiao, MD, PhD, Clementia Pharmaceuticals/Ipsen Pharmaceuticals: Clinical trials site investigator at UCSF, Ultragenyx: Clinical trials site investigator at UCSF

Shingo Kajimura, PhD, Seminar Speaker, Novo Nordisk, Eli Lilly Amgen

Niki Karavataki, MSc, PhD, FRCP, Recordati Rare Diseases, Speaker, HRA Pharma, Speaker, Editorial Board, Pfizer, Speaker, Ipsen, Speaker, Conselient Health, Speaker

Katja Kiseljak-Vassiliades, DO, HRA Pharma, Adrenocortical carcinoma Advisory Board

Ellis R. Levin, MD, Stock Owner: Gilead Inc., Amgen

Raghavendra Mirmira, PhD, MD, Editor: Journal of Clinical Endocrinology and Metabolism, Advisory Board: Veralox Therapeutics

Gabrielle Page-Wilson, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma

Matti Poutanen, PhD, Aboendo, Founder & CEO, Forendo Pharma, Advisor, Organon Co., Advisor

Yumie Rhee, MD, PhD, Associate Editor, JCEM Case Reports

W. Edward Visser, MD, PhD, Royalties (Institution): Egetis Therapeutics

Selma Witchel, MD, Journal of the Endocrine Society, Editorial Board, Steroids, Associate Editor

Bu Beng Yeap, MBBS, FRACP, PhD, Advisory Board: NovoNordisk, Bayer, Advisor: Lawley Pharmaceuticals, Speaker: AstraZeneca, Besins, Philippine Society for Endocrinology, Diabetes and Metabolism, View Street Medical, President: Endocrine Society of Australia, Associate Editor: Asian Journal of Andrology, Journal of Gerontology Medical Sciences, Editorial Board: Journal of Gerontology Medical Sciences, Journal of Clinical Endocrinology and Metabolism, Maturitas

Elaine Wei-Yin Yu, MD, Grant Recipient: Amgen, Stock Owner: Opko

The following AMSC members reported no relevant financial relationships:

Ana Paula Abreu, MD, PhD; Benson Akingbemi, PhD, DVM; Olga Astapova, MD, PhD; Denise Belsham, PhD; Ernesto Bernal-Mizrachi, MD; Daniel Bernard, PhD; Laura Boucai, MD; Davide Calebiro, MD, Barbara Gisella Carranza Leon, MD; Aime Franco, PhD; Hebatullah Ismail, MD; Carolin Hurtado, MD; Srividya Kidambi, MD; T. Raj Kumar, PhD, MPHIL, MSC; Erik Nelson, BSc, PhD; Claire Newton, BSc, PhD; Bernice Omotosho, MD; Ines Pineda Torra PhD; Claudia Ramirez, MD; Kanakadurga Singer, MD; Dominique Stephens, PhD; Marc J. Tetel, PhD; and Jun Yang, MBBS, PhD, FRACP.

Disclosure information for presenters is included in their individual recorded presentations.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.